Is Urolithin A a Good Investment in Healthy Aging?
Any daily supplement is a recurring expense, so it deserves the same scrutiny as any recurring expense. This is a candid look at what your money buys with urolithin A, what the human evidence does and does not yet support, and how to decide whether it earns a place in a healthy-aging budget.
Healthy aging spending tends to fall into a few buckets: things with overwhelming evidence and low cost (sleep, movement, diet, not smoking), things with strong evidence and modest cost (certain vaccines, screenings, a few well-studied nutrients), and things that are promising but still emerging. Urolithin A sits in a specific spot, a compound with a clear biological rationale and a growing but still-developing human evidence base. Deciding whether it is a good investment means being honest about which bucket it is in and pricing it accordingly, rather than reacting to either hype or dismissal. Let us walk through the reasoning.
What you are actually buying: the mechanism
Urolithin A is a gut postbiotic. When you eat ellagitannins from pomegranate, walnuts, and berries, certain gut bacteria can convert them into urolithin A. The wrinkle is that only some people carry the microbes to do this efficiently, so two people eating the same pomegranate can end up with very different urolithin A levels. A standardized supplement removes that lottery by delivering the finished compound directly. Our piece on foods high in urolithin A explains why diet alone is unreliable for this.
The reason the compound draws interest is its proposed role in mitophagy, the cellular process of identifying and recycling worn-out mitochondria so cells can maintain a healthier population of these energy producers. Mitochondrial function tends to decline with age, so a compound that supports this maintenance pathway has an intuitive fit with healthy-aging goals. If you want the underlying biology, see our explainers on what mitophagy is and mitochondrial health. The mechanism is genuinely interesting, but a mechanism is a rationale, not a guarantee, so the value question comes down to the human evidence.
What the human evidence supports today
This is where an honest investment case has to be precise, separating what has been shown in people from what is still preclinical. The most established human findings for urolithin A are in muscle and mitochondrial function. Andreux 2019 (Nature Metabolism), the first-in-human study, established that urolithin A is safe and well tolerated up to 1,000 mg per day and produced a mitochondrial gene-expression signature. Liu and D'Amico 2022 (JAMA Network Open) found improved muscle endurance in older adults over about four months. Singh 2022 (Cell Reports Medicine) reported gains in muscle strength and exercise performance in middle-aged adults over four months at 500 mg and 1,000 mg per day.
The newer human layer is still being built. A 2025 Nature Aging randomized trial of roughly 28 days reported support for immune-cell mitochondrial health in midlife adults, relevant to the low-grade inflammation of aging. A 2024 trial in the Journal of the International Society of Sports Nutrition studied resistance-trained men over eight weeks, and a 2025 trial examined distance runners. These are encouraging but smaller and more recent, and a 2024 systematic review in Ageing Research Reviews fairly concludes that the human evidence for targeting aging with urolithin A is still emerging. So the defensible investment thesis today is muscle, exercise capacity, and mitochondrial support, backed by human trials.
What is still preclinical, and should be priced as such
Some of the most exciting-sounding claims are not yet human findings. Work on joints and cartilage, such as D'Amico 2022 (Aging Cell), comes from osteoarthritis models in animals. The original mitophagy and lifespan findings, from Ryu 2016 (Nature Medicine), were in the roundworm C. elegans and in rodent muscle, not people. Directions like skin, gut, brain, and heart are at an early, preclinical stage of exploration. None of this is a reason to dismiss the compound, but it is a reason not to pay a premium expecting benefits that have only been seen in animals or cells. A sound investment prices in the proven, treats the emerging as upside, and does not bank on the preclinical.
A framework for the decision
Rather than a yes or no verdict, it helps to run urolithin A through a few practical questions.
Does it target something you actually care about?
The strongest human evidence is for muscle strength, endurance, and exercise performance, with mitochondrial and immune-cell support as emerging themes. If maintaining strength and physical capacity as you age is a priority for you, the thesis aligns with your goals. If your concerns are elsewhere, such as skin or cognition, the human evidence is not yet there and the investment is more speculative. Our urolithin A for muscle and urolithin A for energy pages go deeper on those use cases.
Have you funded the free wins first?
The highest-return healthy-aging investments are behavioral and low cost: resistance training, protein-adequate diet, sleep, and movement. These have far stronger evidence than any supplement and, notably, drive the same muscle and mitochondrial outcomes urolithin A is studied for. A supplement is best viewed as a complement layered on top of those foundations, not a substitute. If the basics are not in place, they are the better first investment.
Are you buying the studied dose from a transparent source?
An investment only pays off if the product actually delivers the researched amount. Human studies used 500 to 1,000 mg per day, so a cheaper product at a fraction of that dose is not a bargain, it is a different, unstudied purchase. Confirm the dose, look for third-party testing, and read the label plainly. Our dosage guide and best urolithin A gummies comparison help you judge value across products, and the full urolithin A guide pulls the evidence together.
So, is it worth it?
For someone who has the fundamentals in place, cares specifically about maintaining muscle and mitochondrial function with age, and is comfortable that the broader anti-aging claims are still emerging, daily urolithin A at the studied dose is a reasonable, evidence-informed addition, priced as a modest recurring cost rather than a cure-all. For someone expecting dramatic, whole-body rejuvenation, the human evidence does not yet justify that expectation, and the honest answer is to wait for more research or to invest elsewhere first. A good investment is one whose expected value matches its price, and urolithin A can meet that bar when you buy it for what the human studies actually show.
Frequently asked questions
What does the human evidence for urolithin A actually support?
The strongest human findings are in muscle endurance, strength, and exercise performance, plus safety and a mitochondrial gene-expression signature. Immune-cell mitochondrial support is an emerging human theme. Skin, brain, gut, heart, and joint claims are early or preclinical.
How much does daily urolithin A cost at the studied dose?
SOMA HEALTH Urolithin A Gummies are $79 for a 30-day supply at 1,000 mg per day, roughly $2.63 a day. Whether that is worthwhile depends on how you weigh muscle and mitochondrial support against your other health priorities.
Can I just eat pomegranate and walnuts instead?
You can get the precursors from food, but only some people carry the gut bacteria to convert them into urolithin A efficiently. That variability is the main reason a standardized supplement exists.
Should I take urolithin A instead of exercising?
No. Resistance training, adequate protein, sleep, and movement have far stronger evidence for healthy aging and drive the same muscle and mitochondrial outcomes. Urolithin A is best viewed as a complement on top of those basics, not a replacement.
Is the anti-aging claim proven?
Not in the broad sense. Lifespan findings come from animal and worm models (Ryu 2016), and a 2024 systematic review describes the human anti-aging evidence as still emerging. The defensible human case today is muscle and mitochondrial support.
Is a cheaper urolithin A product a better value?
Only if it delivers the studied dose. Human trials used 500 to 1,000 mg per day, so a product at a fraction of that is an unstudied, different purchase rather than a bargain. Check the dose and third-party testing before comparing on price.
Is urolithin A a treatment for aging or disease?
No. It is a supplement that may support certain structure and function outcomes, not a treatment for any condition. For specific health concerns, see your doctor rather than relying on a supplement.
See SOMA HEALTH Urolithin A Gummies
This guide is educational and is not a treatment for any condition. If you are managing a health concern or take medication, talk with your doctor before starting a new supplement.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →